Pair page
BPC-157 Fragment with GHK-Cu
Mechanism-tag overlap and published literature for BPC-157 Fragment and GHK-Cu, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
derivative-of-bpc-157tissue-repair
connective-tissuecopper-tripeptide-skin
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying BPC-157 Fragment and GHK-Cu have published these mechanism-level observations. Not a co-administration recommendation.
For skin and connective-tissue focus. Different mechanism (copper-dependent gene regulation) from BPC-157 family. Combined as a leaner GLOW-Stack analog when budget is the constraint.
Quick facts
BPC-157 Fragment
GHK-Cu
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2025 | BPC-157 Fragment | Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. PMID: 40756949. (Parent BPC-157 systematic review — does not address fragment-specific evidence; included as… PMID 40756949 | systematic review |
| — | BPC-157 Fragment | ClinicalTrials.gov. Study of PL 14736 in Subjects With Ulcerative Colitis. NCT05765058. (Parent peptide trial — no fragment-specific trial registered.) | human trial |
| 2025 | BPC-157 Fragment | Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025. PMID: 40131143. (Parent peptide human pilot — does not apply to fragment.) PMID 40131143 | human pilot |
| 2024 | BPC-157 Fragment | Lee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Altern Ther Health Med. 2024;30(10):12-17. | human pilot |
| 2020 | BPC-157 Fragment | Xu C, Sun L, Ren F, Huang P, Tian Z, Cui J, et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regul Toxicol Pharmacol. 2020;114:104665. (Parent BPC-157 toxicology — no LD1 in mice/rats/rabbits/dogs.) | preclinical, in vivo |
| — | BPC-157 Fragment | Sikiric P, Seiwerth S, Grabarevic Z, Petek M, Rucman R, Turkovic B, et al. The beneficial effect of BPC 157, a 15 amino acid peptide BPC fragment, on gastric and duodenal lesions induced by restraint stress, cysteamine and 96% ethanol in rats. (Clarifies BPC-157 nomenclature as… | preclinical, in vivo |
| 2025 | BPC-157 Fragment | McGuire FP, Martinez R, Lenz A, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025;18(12):611-619. PMID: 40789979. (Parent peptide; raises evidence-quality concerns applicable to fragment by extension.) PMID 40789979 | review |
| 2024 | BPC-157 Fragment | Sikiric P, Sever M, Krezic I et al. New studies with stable gastric pentadecapeptide protecting gastrointestinal tract, significance of counteraction of vascular and multiorgan failure of occlusion/occlusion-like syndrome in cytoprotection/organ protection. Inflammopharmacology.… | review |
| 2026 | BPC-157 Fragment | WADA Prohibited List 2026. World Anti-Doping Agency. wada-ama.org. (BPC-157 family banned under S0; fragment plausibly included by analogy.) | regulatory / registry |
| 2025 | BPC-157 Fragment | FDA. Bulk Drug Substances That Raise Significant Safety Risks (Category 2) Under Section 503A / 503B. FDA.gov. Updated 2025–2026. (BPC-157 fragment shorter sequences are not specifically listed; parent BPC-157 is Category 2.) | regulatory / registry |
| — | BPC-157 Fragment | USADA. BPC-157: Experimental Peptide Creates Risk for Athletes. U.S. Anti-Doping Agency. usada.org. (Applies to parent and by extension to fragment.) | regulatory / registry |
| 2025 | BPC-157 Fragment | Józwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review. Pharmaceuticals (Basel). 2025;18(2):185. PMID: 40005999. (Parent peptide; reviews structural features including the GE-PPP-GK mot… PMID 40005999 | research article |
| 1995 | GHK-Cu | Buffoni F, Pino R, Dal Pozzo A. Effect of tripeptide-copper complexes on the process of healing of cutaneous wounds in mice. Arch Int Pharmacodyn Ther. 1995;330(3):345-360. PMID: 9060874. PMID 9060874 | preclinical, in vivo |
| 1993 | GHK-Cu | Maquart FX, Bellon G, Chaqour B, Wegrowski J, Patt LM, Trachy RE, et al. In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu²⁺ in rat experimental wounds. J Clin Invest. 1993;92(5):2368-2376. PMID: 8227353. PMID 8227353 | preclinical, in vivo |
| 2011 | GHK-Cu | Hostynek JJ, Dreher F, Maibach HI. Human skin penetration of a copper tripeptide in vitro as a function of skin layer. Inflamm Res. 2011;60(1):79-86. PMID: 20835751. PMID 20835751 | preclinical, in vitro |
| 2007 | GHK-Cu | Pyo HK, Yoo HG, Won CH, Lee SH, Kang YJ, Eun HC, Cho KH, Kim KH. The effect of tripeptide-copper complex on human hair growth in vitro. Arch Pharm Res. 2007;30(7):834-839. PMID: 17702486. PMID 17702486 | preclinical, in vitro |
| 1988 | GHK-Cu | Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu²⁺. FEBS Lett. 1988;238(2):343-346. PMID: 3169264. PMID 3169264 | preclinical, in vitro |
| 2017 | GHK-Cu | Pickart L, Vasquez-Soltero JM, Margolina A. The Effect of the Human Peptide GHK on Gene Expression Relevant to Nervous System Function and Cognitive Decline. Brain Sci. 2017;7(2):20. PMID: 28212278. PMID 28212278 | mechanism / discovery |
| 2012 | GHK-Cu | Campbell JD, McDonough JE, Zeskind JE, Hackett TL, Pechkovsky DV, Brandsma CA, et al. A gene expression signature of emphysema-related lung destruction and its reversal by the tripeptide GHK. Genome Med. 2012;4(8):67. PMID: 22937864. PMID 22937864 | mechanism / discovery |
| 1973 | GHK-Cu | Pickart L, Thaler MM. Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver. Nat New Biol. 1973;243(124):85-87. PMID: 4351857. (Original discovery publication.) PMID 4351857 | mechanism / discovery |
| 2026 | GHK-Cu | WADA Prohibited List 2026. World Anti-Doping Agency. wada-ama.org. | regulatory / registry |
| 2025 | GHK-Cu | FDA. Bulk Drug Substances That Raise Significant Safety Risks (Category 2) Under Section 503A / 503B. FDA.gov. Updated 2025-2026. | regulatory / registry |
| 2018 | GHK-Cu | Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018;19(7):1987. PMID: 29986520. doi:10.3390/ijms19071987. (Comprehensive modern review.) PMID 29986520 | research article |
| 2015 | GHK-Cu | Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int. 2015;2015:648108. PMID: 26236730. PMID 26236730 | research article |
Related pair pages
More research context
Frequently asked
Have BPC-157 Fragment and GHK-Cu been studied together?
Researchers have published mechanistic-level co-administration discussion of BPC-157 Fragment and GHK-Cu. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do BPC-157 Fragment and GHK-Cu share?
BPC-157 Fragment and GHK-Cu do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of BPC-157 Fragment and GHK-Cu?
BPC-157 Fragment: Research-only. GHK-Cu: Cosmetic ingredient; Category 2 for injection. FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on BPC-157 Fragment and GHK-Cu?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the BPC-157 Fragment profile and the GHK-Cu profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026